Ongoing Trials for Other Conditions
In clinical trials nationally, TMS Therapy is showing promise for a number of conditions including Parkinson's disease, schizophrenia, epilepsy, chronic pain, traumatic brain injury, stroke, post traumatic stress disorder, migraine headaches, chronic pain, tinnitus, autism, and Alzheimer's disease.
Researchers at Beth Israel Deaconess Medical Center (BIDMC) are conducting research studies in many of these conditions.
For example, BIDMC was awarded $1.5 million in grants from the Michael J. Fox Foundation for Parkinson's Research (MJFF) to investigate the use of repetitive TMS therapy to control symptoms of Parkinson's disease. As part of the study, 160 patients are being enrolled in clinical trials at BIDMC and other North American centers including the University of Florida in Gainesville, the University of California in Los Angeles, and the Toronto (Canada) Western Research Institute-University of Toronto.
A chronic, degenerative disorder of the nervous system that affects one in 100 individuals over age 60, Parkinson's disease results from diminished levels of dopamine, the brain's chemical messenger responsible for transmitting the signals that enable us to coordinate movements. Although Parkinson's disease typically results in tremor, rigidity and other motor symptoms, a number of non-motor symptoms, including depression, cognitive impairment, and sleep problems can also affect patients with Parkinson's disease and, in many cases, can be even more disabling than the motor symptoms.
BIDMC is also conducting a pilot study on the use of Combined TMS Stimulation and Cognitive Training in Alzheimer's Disease supported by Neuronix Medical. Despite a lot of research, Alzheimer's Disease still presents a huge unmet medical need, and TMS might offer a valuable novel adjunct to cognitive treatments.
Founded in 2008, Neuronix Medical's mission is to find a method for modifying the course of treatment of Alzheimer's Disease, and thus provide long-term improvement in the quality of life for patients.